Back to Journals » Clinical Ophthalmology » Volume 2 » Issue 4

Misregulation of rhodopsin phosphorylation and dephosphorylation found in P23H rat retinal degeneration

Authors Saito Y, Ohguro H, Ohguro I, Sato N, Ishikawa F, Yamazaki H, Metoki T, Ito T, Nakazawa M

Published 5 December 2008 Volume 2008:2(4) Pages 821—828

DOI https://doi.org/10.2147/OPTH.S4359

Review by Single-blind

Peer reviewer comments 2


Yoshiyuki Saito1, Hiroshi Ohguro1, Ikuyo Ohguro1, Noriyuki Sato2, Futoshi Ishikawa3, Hitoshi Yamazaki3, Tomomi Metoki3, Tadashi Ito3, Mitsuru Nakazawa3

1Department of Ophthalmology; 2Department of Pathology (Section 1), Sapporo Medical University School of Medicine, Sapporo, Japan; 3Department of Ophthalmology, Hirosaki University School of Medicine, Hirosaki, Japan

Abstract: To examine rhodopsin (Rho) functions in P23H rat, kinetics of Rho regeneration and dephosphorylation were investigated by spectrophotometric analysis and immunofluorescence labeling method using specific antibodies toward phosphorylated 334Ser or 338Ser site. Rho dephosphorylation at both sites was extremely delayed in P23H retina as compared to normal ones. Kinetics of Rho regeneration was not altered between normal and P23H rats under dark adaptation. Next, to study the effects of several Ca2+ channel blockers on this model, retinal function and morphology were evaluated. Among them, nilvadipine showed a significant protective effect against P23H retinal degeneration. Neurotrophic factor, fibroblast growth factor-2 and Arc, known to suppress the apoptosis in the central nervous system, were significantly upregulated upon administration of nilvadipine. The present study indicates that misregulation of Rho phosphorylation may be involved as an important step in retinal degeneration of P23H and administration of nilvadipine may be a potential therapeutic agent for the retinal degenerations.

Keywords: rhodopsin, P23H rat, retinitis pigmentosa, mutation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]